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 In the opinion of the author, 2013 may someday be seen as an important crossroad in US 
psychopharmacology practice. But the prescribers of psychopharmacology in 2013 may not be paying 
attention to its potentially bleak future as pharmaceutical companies discontinue the development of new 
psychiatric drugs. Instead, psychiatrists may be distracted by the publication of the DSM-5, which has led 
to significant controversies in the field of psychiatric diagnosis. While the future and priorities of 
psychiatry as a medical discipline are not clear, the use of psychopharmacological drugs in the US 
population definitely presents a worrisome paradoxical profile, namely, the obvious undertreatment and 
neglect of severe mental illness and the growing overtreatment of minor psychiatric problems.    
 The author acknowledges that there is an obvious risk in criticizing the current status of US 
psychiatry, since his arguments can be used by psychiatry haters or the media to attack his “beloved” 
medical discipline. Compared with other disciplines, psychiatry is in a weaker position; it shares with 
psychiatric patients the stigma associated with mental illness.  Thus, these critiques are written with the 
ambivalent feeling of a son who publically criticizes a “sick” mother; he wants her to stop denying and 
start facing her problems. This is after many years of thinking that it was not a good idea to openly 
criticize things; it would be better to keep things “private” within the family. Finally, the publication of 
the DSM-5 plus the denial by US psychiatry’s leadership
1
 of its obvious limitations and the possibility of 
legitimate critiques have led him to take the risk of “publicly” exposing his critical ideas.    
PHARMACEUTICAL COMPANIES ARE ABANDONING PSYCHOPHARMACOLOGY 
 In the past few years, the high-profile pharmaceutical companies have decided to shut down major 
research activities in psychopharmacology.
2,3
 This fact has received little attention in 
psychopharmacology journals other than this one.
2
 Only recently, in 2013, has another journal published a 
commentary on this issue.
3
 In 2012, in an important article, Fibiger explained the position of the 
pharmaceutical companies: (1) antipsychotics, antidepressants and anxiolytics were the result of 
serendipitous clinical observation while the research of “the past 3 or 4 decades has failed to generate 
effective, mechanistically novel psychopharmaceuticals” and (2) “the pharmaceutical industry is now well 
*Manuscript
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aware of this fact and has therefore greatly reduced investing.”  Fibiger’s recipe for resolving this 
situation is very painful and requires: (1) major investments in neuroscience research, (2) humility in the 
face of our ignorance, and a (3) willingness to consider fundamental reconceptualizations of psychiatry 
itself.  One would think that hundreds of psychiatrists worried about the future treatment of their patients 
would be commenting on this pessimistic future concerning the development of new and better 
psychiatric drugs. This does not appear to be the case. As of June 12, 2013, there were no published 
articles quoting Fibiger’s article (http://thomsonreuters.com/web-of-science/). Meanwhile, the leaders of 
the National Institute of Mental Health (NIMH) are not worried; they propose to save drug development,
4
 
a slightly less “visionary” view than in 2006
6
 when 21
st
 century psychiatry was only going “to cure” 
mental illness. The NIMH differs from pharmaceutical companies in that it has no stock holders requiring 
a report after this failure. 
THE DISARRAY SURROUNDING THE DSM-5 
     As this journal is read by many professionals who are not psychiatrists, a discussion of US 
psychiatry’s historical “dirty laundry” is needed. Before and during the 1980s, psychiatrists in the US had 
multiple problems but “sectarianism” was probably the first.
7
 In summary, academic psychiatry was 
dominated by psychiatrists with a psychoanalytic approach, poor diagnostic skills and no scientific 
training.
8
 A revolt began at Washington University in St. Louis when psychiatrists there reverted back to 
the diagnostic criteria used by Kraepelin, a German psychiatrist from early in the 20
th 
century. This was 
the so-called neo-Kraepelinian revolution.
9
 The original neo-Kraepelinians, who described 15 psychiatric 
disorders, were worried about validity.
10
 In a major coup, they “converted” Robert Spitzer, a New York 
psychiatrist (New York was probably the sancta sanctorum of psychoanalytic power). Spitzer 
outmaneuvered the psychoanalytic establishment and selected many US psychiatrists contaminated by 
neo-Kraepelinian beliefs to develop the DSM-III criteria; the DSM-III was published by the American 
Psychiatric Association (APA) in 1980. At that time, the DSM-III appeared to be a breath of fresh air that 
allowed the development of biological research psychiatry and made US psychiatry the unquestioned 
 3 
leader of psychiatry around the world. In the process, a “small” inadvertent problem occurred: Spitzer was 
not concerned about the validity of psychiatric diagnostic categories. He had to deal with quarrelsome 
psychiatric experts and decided to focus on agreement between experts and  interrater reliability.
10
 In the 
process, 265 psychiatric disorders were included in the DSM-III.
10
  No one was thinking about the 
possibility that some of these disorders may not be valid. 
 After the DSM-III, the APA published several revisions and/or editions leading to the publication 
of the DSM-5 in May 2013. The paradoxical situation is that one of the major critics of the DSM-5 is 
Allen Frances, who supervised the development of the DSM-IV. Moreover, Frances had to forego using 
US psychiatric journals as a means of criticizing the DSM-5. Recently, he has used an international 
psychiatric journal
11
 and an internal medicine journal
12
 where his recommendation was “to use the DSM-5 
cautiously, if at all.”  The lack of attention to Frances and the exclusion of his criticisms from key 
psychiatric journals appear to the author to be a new form of sectarianism. The author has written articles 
detailing this internal fight about psychiatric diagnoses from the scientific point of view
12
 but this editorial 
focuses on the crucial practical relevance of this fight in reference to the prescription of psychiatric drugs 
in the US.  The author is very worried, as is Frances, that the widening of some psychiatric diagnoses may 
lead to even more prescribing of psychiatric drugs in the US to the wrong patients, while those with more 
severe mental illness are forgotten.  The overdiagnosis of psychiatric disorders in children
14
 appears 
particularly frightening in view of the massive increases of psychopharmacological prescriptions in 
children.
15
 Moreover, the frequent use of  antipsychotics
16
 in children with attention deficit hyperactivity 
disorder (ADHD), an off-label use, verifies the idea that psychiatrists may be expected by society to be 
the leading experts in controlling behaviors in problematic patients independent of whether these 
behaviors are explained by a severe mental illness or not, or whether they really respond to drug 
interventions beyond the goal of “sedating”  patients who are considered  “troublemakers.”          
PARADOXES IN US PSYCHOPHARMACOLOGY PRACTICE 
Overprescription of psychiatric drugs for minor psychiatric disorders  
 4 
 By reviewing the literature, Frances
12
 concluded that in the US psychotropic drugs taken by 20% 
of the US population generate for the pharmaceutical companies $18 billion/year from antipsychotics, $12 
billion from antidepressants, and $8 billion from ADHD drugs. Regarding these costs, there are 
differences in cost between generic and brand names, so costs may be reduced by progressive changes 
from brand names to generics,
17, 16
 but the most important clinical question is whether diagnosing 20% of 
the population taking medications for psychiatric disorders is a number that is too high or too low.  
 This answer is complex. Frances
12
 proposes that 15-20% of the US population has minor 
psychiatric disorders in which it is hard to distinguish the efficacy of drugs from placebos. If we assume 
that this is correct, we may be spending billions on very expensive placebos which, by the way, are not 
innocuous.  Psychiatric drugs can kill you if you decide to overdose or if the occasional potentially lethal 
adverse drug reaction (ADR) occurs when you are taking them as prescribed. Frances appears to get 
psychiatrists off the hook by quoting a 2004-05 study
19
 indicating that 77% of prescriptions for US 
psychiatric drugs are not written by psychiatrists, but mainly by primary care physicians. Frances
12
 
believes that US primary care physicians have too little training and insufficient time with the patient to 
make an accurate psychiatric diagnosis. I do not know your opinion on this issue, but the author’s primary 
care physician, an academic family medicine physician, appears to fit that profile well. The author does 
not see an easy solution to this overprescribing by non-psychiatrists and, in his experience, the prescribing 
practices of many psychiatrists is not much better. Even if we assume that psychiatrists are less prone to 
overprescribe for minor psychiatric disorders that recover spontaneously or with non-specific 
interventions, psychiatrists cannot handle psychiatric care for the 15-20% of the US population with 
minor psychiatric problems. The other option may not be better, as psychiatrists have no systems or 
resources for educating other prescribers about the need to decrease psychiatric medication prescriptions 
in psychiatric disorders that may respond to other interventions or placebo.  
 5 
 To be fair to psychiatry and psychopharmacology, one needs to acknowledge that  pharmaceutical 
companies have flooded the whole medical market with “lifestyle” drugs
20
 for the sake of profit, so drug 
overprescription is not exclusive to psychiatry and is prevalent across all medical specialties.  
Undertreatment of severe mental illness  
  Frances quotes the statistic
12
 that 5% of the US population has a severe mental illness. The 
psychiatric medications of these patients are usually prescribed by psychiatrists. This prevalence sounds 
approximately right, but the sad truth is that there is no standardized definition of severe mental illness. 
Most psychiatrists would not disagree that severe mental illness includes schizophrenia, bipolar disorder 
and severe cases of depression.
21
 The author, who is a “quarrelsome” psychiatrist and likes studying the 
history of psychiatry and psychopharmacology, would also include an additional syndrome, catatonia, 
which has specific treatment responses.
22
 Including catatonia should not increase the prevalence of severe 
mental illness, since in the author’s experience, many US psychiatrists do not know how to diagnose it. 
Unfortunately, non-US authors
23
 report that psychiatrists in other countries also frequently miss the 
diagnosis of catatonia. In summary, catatonia should not increase the prevalence of severe mental illness 
beyond 5% of the US population.   
 This brings us back to psychiatry’s dirty laundry. Patients with severe mental illness were 
“warehoused” in insane asylums during the 19
th
 century in the civilized areas of the US (and Europe). As 
a matter of fact, the APA was founded in 1844 in Philadelphia as the Association of Medical 
Superintendents of American Institutions for the Insane.  Then, between the 1960s and 1980s 
deinstitutionalization took place in the US and the treatment for these deinstitutionalized people with 
severe mental illness was poorly funded and separate from the medical treatment of the general 
population.
24
 It may not be familiar to non-psychiatrists that, according to a 2010 review,
25
 the US houses 
three times more severely mentally ill people in prison that in psychiatric hospitals and that 40% of those 
hospitalized have been in jail or prison at some time in their lives. Thus, although this has not reached 
PubMed and is only recently reaching the media,
26
 psychiatrists working in the penal system are starting 
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to call jails and prisons the “new asylum”.
27
 US society as whole is ignoring the fact that this way of 
“storing” patients with severe mental illness is not only “inhumane” but very expensive.
28
 In 2013, 
newspapers all over the country reported significant cuts in state mental health budgets that unequivocally 
will lead to more people with severe mental illness entering the penal system.  Simultaneously, no plans 
exist for integrating people with severe mental illness into the new health system that the US is trying to 
develop.  
 TV and other media project the paradoxical viewpoints that sometimes psychiatrists are “evil 
controllers” when they are trying to use proven and effective treatments for severe mental illness while at 
other times psychiatrists are presented as extraordinarily effective in controlling behaviors not explained 
by severe mental illness that in real life do not respond to psychiatric medications. These paradoxical 
extremes of undertreatment and overtreatment have also tainted the psychopharmacology practice of the 
author, a psychiatrist, within the last year. In the process of educating and supervising residents and 
practicing psychiatrists from the public system who consult him, he has found himself continuously 
stressing the need for more and better treatment for inpatients with severe mental illness and less 
psychopharmacological treatment for outpatients with minor psychiatric problems. The worst distress of 
the year was finding that undiagnosed catatonia continues to be lethal in the US. The most frequent 
annoyance of the year was reviewing outpatient treatment with residents, which frequently led to the 
recommendation to stop medications when the patient was willing to consider that option, or at least 
question the psychiatric polypharmacy, which was not justified, due to the lack of an obvious genuine 
diagnosis of severe mental illness. 
Conclusion 
 This editorial proposes that 2013 may be viewed in the future as a crossroad for psychiatry, with 
paradoxical pressures and messages to practicing psychiatrists including (1) the NIMH’s assurance not to 
worry because it can be successful where pharmaceutical companies have failed, since new and better 
psychiatric drugs are forthcoming; and (2) the APA’s encouragement to use the DSM-5, which further 
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increases the prevalence of mental illness, and its apparent agreement with overprescription of psychiatric 
medications to control behaviors even if they are not explained by severe mental illness. Other long-term 
pressures and messages emanate from (1) pharmaceutical companies, with the assistance of media, that 
continue to encourage drug use for “lifestyle” enhancement; and (2) TV and other media that continue to 
project the paradoxical viewpoints that sometimes psychiatrists are “evil controllers” when they are trying 
to use proven and effective treatments for severe mental illness while at other times psychiatrists are 
presented as extraordinarily effective in controlling behaviors not explained by severe mental illness that 
in real life do not respond to psychiatric medications. The most important unheard message which 
everyone ignores (including the NIMH and the APA) is that people with severe mental illness are not 
receiving the appropriate treatment and that budgets for psychiatric treatment are “evaporating”.  As a 
result, these patients will increasingly be placed in the penal system, the “new asylum.”  If the trend 
continues, and there is no sign that it will not, psychiatrists may need to rename themselves “alienists,”
25
 
as in the 19
th
 century. As a matter of fact, if psychiatrists do not consider well their priorities and the 
realities of the 21
st
 century, they may be practicing like 19
th
 century alienists with the only improvement 
being access to serendipitous drug discoveries from the 20
th
 century.
3
  
 Finding solutions for this complex set of problems facing US psychiatry at the beginning of the 
21
st
 century is crucial not only for US psychiatry but for world psychiatry, since US psychiatry became 
the undisputed world leader with the DSM-III.  Meanwhile, European psychiatry appears to have been 
asleep
29
since then, and East Asian psychiatry is only beginning to take its first steps.
13
 The needs for 1) a 
comprehensive research approach which acknowledges that psychiatry is a hybrid discipline,
30
 and 2) a 
greater research focus on the social sciences for defining many of the minor psychiatric disorders listed in 
the DSM-5 have been described in articles by the author
13
 and others.
30,31
 The need for a comprehensive 
approach to better training psychiatrists in what was called descriptive psychopathology and for 
modifying psychiatric nosology is described in articles by the author
13,29
 and others.
32
  Moreover, a new 
21
st
 century nomenclature for describing psychiatric symptoms and disorders using current knowledge 
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may be needed.
13,33
  Although the author is somewhat pessimistic about psychiatry, he is much more 
optimistic about the possibility of improving psychopharmacology. Fifteen years ago, he decided that the 
scientific approach had a much more promising future in psychopharmacology than in psychiatry as a 
whole, and decided to retrain himself as a pharmacologist by learning more about the pharmacokinetic 
and pharmacodynamic mechanisms of each psychiatric drug so as to better personalize treatment in each 
patient.
34
 As psychiatric drugs were mainly a product of serendipity, he is not sure when new 
breakthroughs will occur, but he is very sure that we can do a much better job in training psychiatry 
residents and other prescribers by combining the evidence-based approach with pharmacokinetic and 
pharmacodynamic knowledge in a practical way to better use each psychiatric drug in each patient.
35
  
Moreover, a better job can be done
13
 in stressing the crucial role of medications (and electroconvulsive 
therapy) in severe mental illness versus the limited role and serious consideration of the medication risks 
in minor psychiatric disorders, which may respond to other interventions including psychotherapy. 
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